<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04553081</url>
  </required_header>
  <id_info>
    <org_study_id>BC-7052</org_study_id>
    <nct_id>NCT04553081</nct_id>
  </id_info>
  <brief_title>2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial</brief_title>
  <acronym>2DR</acronym>
  <official_title>Virological and Immunological Assessment in HIV Positive Participants on 2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to monitor virological and immunological markers in participants who&#xD;
      are switching from a classic triple drug regimen (3DR) to dual therapy (2DR). We aim to&#xD;
      monitor whether this has an influence on different parameters such as severity of HIV disease&#xD;
      (evaluated by viral load and viral reservoir size), presence of non-AIDS related health&#xD;
      complications, impact the phenotype and function of the immune system.&#xD;
&#xD;
      By conducting this study we want to assess whether switching from 3DR to 2DR implies an&#xD;
      increased risk for 'subclinical' failure. We especially want to make sure that this switch&#xD;
      does not increase the HIV reservoir, does not increase inflammation or immune exhaustion in&#xD;
      patients living with HIV and that it can be considered as a safe long term alternative for&#xD;
      the classic 3DR.&#xD;
&#xD;
      The primary objective is to demonstrate non inferiority at W48 of the 2DR DTG/3TC (Dovato)&#xD;
      regimen compared to BIC/TAF/FTC (Biktarvy) in terms of the amount of intact replication&#xD;
      competent HIV sequences with a non-inferiority margin of 12% quantified by the fraction&#xD;
      intact HIV viral sequences quantified by IPDA, present in blood CD4 cells.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 26, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in amount of intact replication-competent HIV-1 sequences in CD4 cells between 2 regimens</measure>
    <time_frame>48 weeks</time_frame>
    <description>The primary objective is to demonstrate non inferiority at W48 of the 2DR DTG/3TC (Dovato) regimen compared to BIC/TAF/FTC (Biktarvy) in HIV-1 infected individuals in terms of the amount of intact replication-competent HIV-1 sequences with a non-inferiority margin of 12% quantified by the fraction intact HIV viral sequences quantified by IPDA, present in blood CD4 cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Full length sequencing of the virus</measure>
    <time_frame>144 weeks</time_frame>
    <description>Full length sequencing of the virus at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of interleukin-6 (IL-6)</measure>
    <time_frame>144 weeks</time_frame>
    <description>Quantification of IL-6 at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of high-sensitivity C-reactive protein (hs-CRP)</measure>
    <time_frame>144 weeks</time_frame>
    <description>Quantification of hs-CRP at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of D-Dimers</measure>
    <time_frame>144 weeks</time_frame>
    <description>Quantification of D-Dimers at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of Human Leukocyte Antigen - DR isotype (HLA-DR)</measure>
    <time_frame>144 weeks</time_frame>
    <description>Quantification of HLA-DR at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of cluster of differentiation 38 (CD38)</measure>
    <time_frame>144 weeks</time_frame>
    <description>Quantification of CD38 on both cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) immune cells at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of soluble cluster of differentiation 27 (sCD27)</measure>
    <time_frame>144 weeks</time_frame>
    <description>Quantification of sCD27 at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of soluble cluster of differentiation 40 (sCD40)</measure>
    <time_frame>144 weeks</time_frame>
    <description>Quantification of sCD40 at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of programmed cell death protein 1 (PD-1)</measure>
    <time_frame>144 weeks</time_frame>
    <description>Quantification of the T cell exhaustion marker PD-1 at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of cluster of differentiation 28 (CD28)</measure>
    <time_frame>144 weeks</time_frame>
    <description>Quantification of the T cell exhaustion marker CD28 at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of cluster of differentiation 57 (CD57)</measure>
    <time_frame>144 weeks</time_frame>
    <description>Quantification of the T cell exhaustion marker CD57 at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of soluble cluster of differentiation 14 (sCD14)</measure>
    <time_frame>144 weeks</time_frame>
    <description>Quantification of markers of microbial translocation sCD14 at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of CD4/CD8 ratio</measure>
    <time_frame>144 weeks</time_frame>
    <description>Quantification of CD4/CD8 ratio at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of metabolic syndrome</measure>
    <time_frame>144 weeks</time_frame>
    <description>Metabolic health will be assessed through incidence of metabolic syndrome at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight/body mass index (BMI) change</measure>
    <time_frame>144 weeks</time_frame>
    <description>Metabolic health will be assessed through weight/BMI change at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>144 weeks</time_frame>
    <description>Metabolic health will be assessed through waist circumference at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insuline resistance</measure>
    <time_frame>144 weeks</time_frame>
    <description>Metabolic health will be assessed through insuline resistance at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dual-energy x-ray absorptiometry (DXA)</measure>
    <time_frame>144 weeks</time_frame>
    <description>Bone mineral density will be assessed through DXA at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FibroScans</measure>
    <time_frame>144 weeks</time_frame>
    <description>Fat distribution will be assessed through FibroScans at baseline, W48 and W144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Switch questionnaire</measure>
    <time_frame>144 weeks</time_frame>
    <description>The impact of switching will be assessed through a patient switch questionnaire at baseline, W48 and W144</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Dovato</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>We aim to include 134 adult HIV-infected patients with HIV RNA &lt; 50 copies/mL for at least 3 months on any stable 2nd generation integrase based triple therapy antiretroviral regimen. Patients will be randomized 1:2 to switch to or stay on the triple regimen BIC/TAF/FTC (Biktarvy) (N=45) or to switch to the dual regimen DTG/3TC (Dovato) (N=89).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biktarvy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>We aim to include 134 adult HIV-infected patients with HIV RNA &lt; 50 copies/mL for at least 3 months on any stable 2nd generation integrase based triple therapy antiretroviral regimen. Patients will be randomized 1:2 to switch to or stay on the triple regimen BIC/TAF/FTC (Biktarvy) (N=45) or to switch to the dual regimen DTG/3TC (Dovato) (N=89).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual versus triple therapy in treatment of HIV-1 infection.</intervention_name>
    <description>cfr arm decsription</description>
    <arm_group_label>Biktarvy</arm_group_label>
    <arm_group_label>Dovato</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age = or &gt;18 years.&#xD;
&#xD;
          -  Ability and willingness to provide written informed consent.&#xD;
&#xD;
          -  Ability to attend the complete schedule of assessments and patient visits.&#xD;
&#xD;
          -  Ability and willingness to have blood samples collected and stored indefinitely and&#xD;
             used for various research purposes.&#xD;
&#xD;
          -  HIV RNA &lt; 50 copies/mL for at least 3 months on a 2nd generation INSTI based regimen.&#xD;
&#xD;
          -  Females of childbearing potential should be on effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current presence of opportunistic infection (AIDS defining events as defined in&#xD;
             category C of the CDC clinical classification).&#xD;
&#xD;
          -  Evidence of active HBV infection (Hepatitis B surface antigen positive or HBV viral&#xD;
             load positive in the past and no evidence of subsequent seroconversion&#xD;
             (seroconversion= HBV antigen or viral load negative and positive HBV surface&#xD;
             antibody).&#xD;
&#xD;
          -  Evidence of active HCV infection: HCV antibody positive result within 60 days prior to&#xD;
             study entry with positive HCV viral load or, if the HCV antibody result is negative, a&#xD;
             positive HCV RNA result within 60 days prior to study entry.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Patients unable to understand the study protocol or any other condition that in the&#xD;
             investigator's opinion may compromise compliance with the study protocol&#xD;
&#xD;
          -  Decompensated liver cirrhosis (Child-Pugh B/C)&#xD;
&#xD;
          -  Unstable liver disease (as defined by the presence of ascites, encephalopathy,&#xD;
             coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice),&#xD;
             cirrhosis, known biliary abnormalities (apart from hyperbilirubinemia or jaundice due&#xD;
             to Gilbert's syndrome or asymptomatic gallstones)&#xD;
&#xD;
          -  Psychiatric and psychological disorders, which in the opinion of the investigator,&#xD;
             will interfere with the trial conduct or safety of the participant.&#xD;
&#xD;
          -  Previous participation in a trial evaluating an immune modulating agent.&#xD;
&#xD;
          -  Active drug or alcohol use/addiction such that, in the opinion of the site&#xD;
             investigator, would interfere with adherence to study requirements.&#xD;
&#xD;
          -  Treatment failure on an integrase inhibitor containing regimen and reported baseline&#xD;
             resistance&#xD;
&#xD;
          -  Creatinine Clearance &lt;50&#xD;
&#xD;
          -  Tuberculosis treatment&#xD;
&#xD;
          -  Documented M184V&#xD;
&#xD;
          -  Previous virological failure &gt;200 copies/mL on NRTI&#xD;
&#xD;
          -  Subjects with history or presence of allergy to any of the study drugs or their&#xD;
             components&#xD;
&#xD;
          -  ALT &gt;5 times the ULN, OR ALT &gt;3xULN and bilirubin &gt;1.5xULN (with &gt;35% direct&#xD;
             bilirubin)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linos Vandekerckhove</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>dual therapy</keyword>
  <keyword>triple therapy</keyword>
  <keyword>virological control</keyword>
  <keyword>immune activation</keyword>
  <keyword>metabolic complications</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

